Target the Gene
Silence the Disease
Pipeline
Drug(Disease)
Disease
Pre-clinical
Pre-IND
Phase 1
Phase 2
Phase 3
-
ARO-AAT (Alpha-1 Liver Disease)Alpha-1 Liver Disease
-
ARO-APOC3 (Hypertriglyceridemia)Hypertriglyceridemia
-
ARO-ANG3 (Dyslipidemia)Dyslipidemia
-
ARO-HSD (Liver Disease)Liver Disease
-
ARO-ENaC (Cystic Fibrosis)Cystic Fibrosis
-
ARO-HIF2 (Renal Cell Carcinoma)Renal Cell Carcinoma
-
JNJ-3989 (Hepatitis B)Hepatitis BLicensed to Janssen
-
AMG 890 (Cardiovascular Disease)Cardiovascular DiseaseLicensed to Amgen
-
ARO-JNJ1 (Undisclosed)UndisclosedPartnered with Janssen
- Liver
- Lung
- Tumor
Science
Arrowhead has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies.
Learn MoreAbout Arrowhead
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.
Learn More